Income statement
USD
Annual
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 192M | 184M | 158M | 130M | 80M |
| Gross Profit | 153M | 146M | 126M | 103M | 63M |
| Operating Income | 6M | 11M | 23M | 22M | 10M |
| EBITDA | 11M | 18M | 26M | 25M | 12M |
| Net Income | 3M | 10M | 17M | 17M | 9M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.055
-8.33% today
Window Change
-97.70%
Window
Jun 23, 2025 → Mar 26, 2026
Historical coverage is still expanding
This 1Y daily history view is usable, but not fully loaded yet. Additional bars will appear as backfills continue.
Coverage: 192 bars · Jun 23, 2025 → Mar 26, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Zynex, Inc. (ZYXIQ) is a Healthcare stock with a market cap of $1.69M and listed on OTC. The stock last traded around $0.06 and down 97.7% across the available one-year price window (Jun 23, 2025 → Mar 26, 2026). Baseline metrics include revenue growth of +4.4%, EPS growth of -65.3%, a dividend yield of 0.0%. What stands out right now is revenue +4.4%, EPS -65.3%, free cash flow -26.6% with operating margin -62.8% and ROIC -224.5%. Valuation is more restrained than many high-expectation growth names at price/sales 0.0. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines ZYXIQ price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
ZYXIQ
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
ZYXIQ Max Drawdown
-98.85%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for ZYXIQ and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$80.1M
-38.5% YoY
FY Net Income
$9.1M
-46.9% YoY
Free Cash Flow
-$167.0K
-102.6% YoY
Revenue Growth
+4.4%
EPS Growth
-65.3%
Gross Margin
71.6%
Net Margin
-68.4%
Income statement
USD
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 192M | 184M | 158M | 130M | 80M |
| Gross Profit | 153M | 146M | 126M | 103M | 63M |
| Operating Income | 6M | 11M | 23M | 22M | 10M |
| EBITDA | 11M | 18M | 26M | 25M | 12M |
| Net Income | 3M | 10M | 17M | 17M | 9M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Cash & Equivalents | 40M | 45M | 20M | 43M | 39M |
| Total Assets | 122M | 137M | 120M | 133M | 72M |
| Total Liabilities | 86M | 91M | 54M | 59M | 15M |
| Shareholder Equity | 36M | 46M | 66M | 74M | 57M |
| Total Debt | 74M | 76M | 27M | 38M | 7M |
| Net Debt | 34M | 32M | 7M | -5M | -32M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
818K
-88.2% YoY
Capital Expenditures
985K
-61.7% YoY
Free Cash Flow
167K
-102.6% YoY
Key ratios
Gross Margin
71.6%
Operating Margin
-62.8%
Net Margin
-68.4%
ROE
-1807.0%
Debt / Equity
-1.73x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.